Category Research

Seaport Therapeutics Publishes Research on Glyph™ Platform’s 55% Lymphatic Drug Absorption

Seaport Therapeutics (“Seaport” or the “Company”), a clinical-stage biopharmaceutical company specializing in novel neuropsychiatric medicines, has announced the publication of groundbreaking research on its Glyph™ platform. The study, published in Molecular Pharmaceutics, highlights the platform’s unique ability to improve drug…

Read MoreSeaport Therapeutics Publishes Research on Glyph™ Platform’s 55% Lymphatic Drug Absorption

GenSight Biologics Reports Five-Year Efficacy and Safety Results of LUMEVOQ® Gene Therapy from the REFLECT Study

GenSight Biologics Reports Five-Year Efficacy and Safety Results of LUMEVOQ® Gene Therapy from the REFLECT Study GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharmaceutical company dedicated to developing and commercializing innovative gene therapies for neurodegenerative retinal diseases and…

Read MoreGenSight Biologics Reports Five-Year Efficacy and Safety Results of LUMEVOQ® Gene Therapy from the REFLECT Study

Protein Prediction LG Develops AI-Powered Protein Prediction for Drug Discovery

Protein Prediction LG Develops Next-Generation AI for Protein Structure Prediction to Revolutionize Drug Discovery On February 5th, LG AI Research took a significant step in advancing the field of artificial intelligence-driven biotechnology by signing a joint research agreement with Professor…

Read MoreProtein Prediction LG Develops AI-Powered Protein Prediction for Drug Discovery

Antibodies.com & Cactus Partner to Speed Up Life Science Publishing

Antibodies.com and Cactus Communications Partner to Accelerate Life Science Manuscript Publication Antibodies.com, a leading provider of high-quality biological reagents for life science researchers, has announced a strategic partnership with Cactus Communications (CACTUS), a global leader in science communication and technology.…

Read MoreAntibodies.com & Cactus Partner to Speed Up Life Science Publishing
Pharmascience

Pharmascience Signet, Athyrium, Hildred Successfully Exit Pharmaceutics International

Signet Healthcare Partners, Athyrium Capital Management, Hildred Capital, and Pharmascience Announce Exit from Pharmaceutics International, Inc. A consortium of investors, including Pharmascience Signet Healthcare Partners, Athyrium Capital Management, Hildred Capital, and Pharmascience has successfully exited its equity stake in Pharmaceutics…

Read MorePharmascience Signet, Athyrium, Hildred Successfully Exit Pharmaceutics International
Clinical Applications

Clinical Applications Expert Hong Jiang, MD, PhD, Excels in Translating Scientific Discoveries

Dr. Hong Jiang: Advancing Immunology from Scientific Breakthroughs to Clinical Applications Dr. Hong Jiang, MD, PhD, has been recognized in Marquis Who’s Who for her outstanding contributions to immunology and biomedical research. Marquis Who’s Who selects individuals based on their…

Read MoreClinical Applications Expert Hong Jiang, MD, PhD, Excels in Translating Scientific Discoveries
Clinical Research

Clinical Research Leader Claxton Copeland III Honored by Marquis Who’s Who

Claxton Copeland III Recognized for Excellence in Clinical Research Claxton Copeland III has been selected for inclusion in Marquis Who’s Who, a prestigious recognition that highlights individuals based on their accomplishments, visibility, and impact within their respective fields. His selection…

Read MoreClinical Research Leader Claxton Copeland III Honored by Marquis Who’s Who

Phase 1 Data Prolong Pharmaceuticals to Present Preliminary PP-007 Findings for AIS at 2025 ISC

Prolong Pharmaceuticals to Present Preliminary Phase 1 Data for PP-007 in AIS at 2025 ISC Phase 1 Data Prolong Pharmaceuticals, LLC, a clinical-stage biopharmaceutical company, is poised to make a significant contribution to the field of acute ischemic stroke (AIS)…

Read MorePhase 1 Data Prolong Pharmaceuticals to Present Preliminary PP-007 Findings for AIS at 2025 ISC

Turn Therapeutics Achieves 24-Hour Stability for Intranasal Live Vaccine at Room Temperature

Turn Therapeutics Achieves 24-Hour Stability for Intranasal Live Vaccine at Room Temperature Turn Therapeutics has made a groundbreaking achievement in vaccine preservation by successfully maintaining the viability of a live vaccine for 24 hours at room temperature using its innovative…

Read MoreTurn Therapeutics Achieves 24-Hour Stability for Intranasal Live Vaccine at Room Temperature
Vaccines

Vaccines and Therapeutics Africa & Europe Partner to Advance RNA-Based Solutions

Africa and Europe Unite to Revolutionize RNA-Based Vaccines and Therapeutics Production In a groundbreaking collaboration, Africa’s EVA Pharma, France’s DNA Script, and Belgium’s Quantoom Biosciences have signed a Memorandum of Understanding (MoU) to establish an innovative end-to-end RNA-based vaccine and…

Read MoreVaccines and Therapeutics Africa & Europe Partner to Advance RNA-Based Solutions
Cardio Diagnostics

Cardio Diagnostics Partners with 7 Providers to Expand AI-Driven Cardiovascular Tests

Cardio Diagnostics Expands Reach with New Partnerships to Transform Heart Disease Prevention and Management Cardio Diagnostics Holdings a leading company in AI-driven Precision Cardiovascular Medicine, has announced the expansion of its innovative solutions with seven new provider partnerships. This strategic…

Read MoreCardio Diagnostics Partners with 7 Providers to Expand AI-Driven Cardiovascular Tests